Nanotech Investing Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List 07 December
Nanotech Investing Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology 03 December
Nanotech Investing Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update 03 November
